Drugs / AFN-12520000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01519492 | Feb → Aug 2012 | abscess, cellulitis, skin infection | Affinium Pharmaceuticals, Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFN-12520000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01519492 ↗ |
| Action | Inhibit | “a selective inhibitor of Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI)” PMID 26711777 ↗ Dec 2015 |
| Route | Oral | “given by mouth twice daily” PMID 26711777 ↗ Dec 2015 |